• Hikmet Akkiz, Brian I Carr, Harika G Bag, Ümit Karaoğullarından, Kendal Yalçın, Nazim Ekin, Ayşegül Özakyol, Engin Altıntaş, Hatice Y Balaban, Halis Şimşek, Ahmet Uyanıkoğlu, Ayhan Balkan, Sedef Kuran, Oğuz Üsküdar, Yakup Ülger, Burak Güney, and Anil Delik.
• Çukurova University, Adana, Turkey.
• Int. J. Clin. Pract. 2021 Feb 1; 75 (2): e13593.

IntroductionHepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important.ObjectiveTo evaluate the serum levels of three inflammation markers in relation to survival in HCC patients.MethodsWe retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival.ResultsSurvival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3-fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors.ConclusionsCombinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.© 2020 John Wiley & Sons Ltd.

8 keywords...

hide…